Achieva Medical Entered into an Exclusive Distribution Agreement with NowYon Medical

August 28, 2024 06:40 PM AEST | By Cision
Follow us on Google News: https://kalkinemedia.com/resources/assets/public/images/google-news.webp

SUZHOU, China, Aug. 28, 2024 /PRNewswire/ -- Peijia Medical (HKG:9996), a leading Chinese domestic player in the high-growth transcatheter valve therapeutics and neurovascular interventions markets, announced that its wholly-owned subsidiary, Achieva Medical Limited ("Achieva Medical"), entered into an exclusive distribution agreement with Jiangsu NowYon Medical Limited ("NowYon Medical"). The agreement marks a significant milestone in the expansion of Peijia Medical's Neurointerventional Business in the Greater China region.

Under the terms of the agreement, Achieva Medical has been appointed as the exclusive distributor for NowYon Medical's innovative YonFlow® flow diverter, the first retrievable stent system after complete release globally. In January 2023, the product passed the innovative medical device review and was accepted by the Special Review and Approval Procedure for Innovative Medical Devices of the National Medical Products Administration (NMPA). In addition, the application for the registration approval of YonFlow® has been submitted to the NMPA, which is expected to be approved soon.

"This strategic collaboration with NowYon Medical is a testament to our commitment to bringing cutting-edge medical solutions to patients in need and will continue to consolidate our leading position in the neurovascular interventions market in China." said Dr. Yi Zhang, Chairman and CEO of Peijia Medical. "We are excited about the potential of the YonFlow® flow diverter and its impact on improving patient outcomes."

About Peijia Medical
Peijia Medical (9996.HK) was established in 2012 and is headquartered in Suzhou, China. Peijia Medical focuses on the high-growth interventional procedural medical device market in China and aims to become a world-renowned medical device platform that provides comprehensive treatment solutions for structural heart and neurovascular diseases. The Company now has three TAVR systems and sixteen neurointerventional devices commercialized in China and various innovative product candidates at different stages of development.

For more information about Peijia, please visit peijiamedical.com/about.

About Achieva Medical
Achieva Medical, a wholly-owned subsidiary of Peijia Medical (9996.HK), is an innovative medical device company committed to development and manufacture of high-end neurointerventional medical devices. Achieva Medical now has sixteen commercialized products and various product candidates at different stage of development covering hemorrhagic stroke, ischemic stroke and vascular access.

About NowYon Medical
NowYon Medical is an innovative medical device company focusing on the development and manufacture of neurointerventional medical devices. Its product pipeline encompasses a range of solutions for hemorrhagic stroke, ischemic stroke and vascular access, including flow diverters, stent retrievers, aspiration catheters, balloon microcatheter, microcatheter, etc.

 


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.

This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.

Two ASX Listed Stocks Giving Bullish Indications

Recent Articles

Investing Tips

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.